NORDITROPIN NORDIFLEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORDITROPIN NORDIFLEX (NORDITROPIN NORDIFLEX).
Norditropin is a recombinant human growth hormone (rhGH) that binds to growth hormone receptors, activating JAK2/STAT5, MAPK, and PI3K/Akt pathways, leading to increased IGF-1 production, linear growth, protein synthesis, and lipolysis.
| Metabolism | Hepatic degradation via proteolysis; renal catabolism; not metabolized by CYP450 enzymes. |
| Excretion | Renal: >90% of administered dose excreted via urine, primarily as intact somatropin and its metabolites. Biliary/fecal: <10%. |
| Half-life | Intravenous: 0.6 hours; subcutaneous: 3-4 hours due to slow absorption. Terminal half-life is 1-2 hours, with clinical effects persisting longer due to tissue distribution. |
| Protein binding | Approximately 40-50% bound to growth hormone-binding protein (GHBP) and other serum proteins, mainly albumin. |
| Volume of Distribution | 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues. |
| Bioavailability | Subcutaneous: Approximately 80%. Intramuscular: similar but less utilized. Intravenous: 100% by definition. |
| Onset of Action | Subcutaneous: Peak serum levels at 3-5 hours; IGF-1 elevation begins within 3-6 hours. Clinical effects (growth) require weeks of therapy. |
| Duration of Action | Subcutaneous: IGF-1 levels remain elevated for 12-24 hours. Clinical growth effects persist with daily dosing. Once-daily dosing maintains therapeutic levels. |
0.15-0.3 mg subcutaneously daily
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based modifications; use with caution in severe renal impairment. |
| Liver impairment | No specific Child-Pugh based modifications; use with caution in severe hepatic impairment. |
| Pediatric use | 0.024-0.034 mg/kg subcutaneously daily (6-7 days per week); dose may be titrated based on response. |
| Geriatric use | No specific elderly dose adjustments; consider lower starting doses due to increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORDITROPIN NORDIFLEX (NORDITROPIN NORDIFLEX).
| Breastfeeding | Excreted in human milk; unknown effects on infant. M/P ratio not reported. Caution advised. |
| Teratogenic Risk | Limited human data; no evidence of teratogenicity in animal studies. Risk cannot be excluded. Use only if clearly needed. |
| Fetal Monitoring | Monitor fetal growth via ultrasound; assess maternal blood glucose and thyroid function. Check for signs of intracranial hypertension. |
■ FDA Black Box Warning
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure; contraindicated in pediatric patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (risk of sudden death); potential for increased neoplastic risk; not for use in children with closed epiphyses.
| Serious Effects |
["Acute critical illness (e.g., open heart surgery, abdominal surgery, multiple trauma, acute respiratory failure)","Pediatric patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment","Active malignancy (except for treatment of growth hormone deficiency secondary to intracranial tumors) – discontinue if evidence of tumor growth","Diabetic retinopathy (active proliferative or preproliferative)","Hypersensitivity to somatropin or any excipients","Closed epiphyses (for linear growth indication)"]
| Precautions | ["Risk of neoplasia (monitor for new or recurrent malignancy)","Intracranial hypertension (papilledema, headache, visual changes) – discontinue if papilledema","Slipped capital femoral epiphysis (hip/knee pain, limp) – evaluate","Pancreatitis – monitor for abdominal pain","Fluid retention (peripheral edema, arthralgia, carpal tunnel), especially in adults","Endocrine disorders (hypothyroidism, adrenal insufficiency) – monitor and treat","Glucose intolerance / diabetes mellitus – monitor blood glucose","Progression of scoliosis in children","Otitis media and cardiovascular effects in Turner syndrome"] |
Loading safety data…
| Fertility Effects | May restore fertility in growth hormone-deficient women. No known adverse effects on fertility. |